Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve

Cancer Research

Volumn 65, Issue 23, 2005, Pages 11044-11050

  Celik, Ilhan ^a,f   Sürücü, Oguzkan ^a   Dietz, Carsten ^a   Heymach, John V ^c,e   Force, Jeremy ^c   Höschele, Iris ^a   Becker, Christian M ^b,c,d   Folkman, Judah ^c   Kisker, Oliver ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLIN D1; ENDOSTATIN; GLYPICAN; VASCULOTROPIN; VERY LATE ACTIVATION ANTIGEN 5;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER; CELL MIGRATION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOSTATINS; ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, SCID; PANCREATIC NEOPLASMS; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 28244462515     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2617     Document Type: Article

References (49)

1. Folkman J, Kalluri R. Tumor angiogenesis. 6th ed. In: Kufe D, Pollock R, Weichselbaum R, Bast R, Gansler T, Holland J, et al., editors. Cancer Medicine 6, 2003. p. 161-94.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenetic inhibitors, World J Surg 2003; 27:1-7.
4. Schuch G, Kisker O, Atala A, Soker S. Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. Angiogenesis 2002; 5:181-90.
5. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
6. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
7. Eriksson K, Magnussori P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003;536:19-24.
8. Takahashi K, Saishin Y, Saishin Y, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascuarization, and retinal detachment. FASEB J 2003;17:896-8.
9. 1 and caveolin-I, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002; 62:5580-9.
10. Karumanchi SA, Jha V, Ramchandran R, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001;7:811-22.
11. Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB J 2001;15:1044-53.
12. Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002;277:16464-9.
13. Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1, J Biol Chem 2002; 277:27872-9.
14. Hajitou A, Grignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002;16:1802-4.
15. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3: 422-33.
16. Abdollahi A, Hahnfeldt P, Maercker C, et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13:649-63.
17. Schuch G, Heymach JV, Nomi M, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells, Cancer Res 2003;63:8343-50.
18. Trinh L, Noronha SB, Fannon M, Shiloach J. Recovery of mouse endostatin produced by Pichia pastoris using expanded bed adsorption. Bioseparation 2000;9:223-30.
19. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001;61:7669-74.
20. Wickstrom SA, Alitalo K, Keski-Oja J. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004;279:20178-85.
21. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4.
22. Heymach JV, Kulke MH, Fuchs CS, et al. Circulating endothelial cells as a surrogate marker of antiangiogenic activity in patients treated with endostatin [Abstract]. Proc Am Soc Clin Oncol 2003;22:244.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizunab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
24. Kisker O, Onizuka S, Banyard J, et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 2001;61:7298-304.
25. Kisker O, Onizuka M, Becker CM, et al. Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 2003;5:32-40.
26. O'Mahony CA, Seidel A, Albo D, Chang H, Tuszynski GP, Berger DH. Angiostatin generation by human pancreatic cancer. J Surg Res 1998;77:55-8.
27. Ma L, Del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci U S A 2002;99:13243-7.
28. Kuo CJ, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 2001;98:4605-10.
29. Eisterer W, Jiang X, Bachelot T, et al. Unfulfilled promise of endostatin in a gene: therapy-xenotransplant model of human acute lymphocytic leukemia, Mol Ther 2002;5:352-9.
30. Marshall E. Cancer therapy. Setbacks for endostatin. Science 2002;295:2198-9.
31. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther 2002;9:513-21.
32. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194-201.
33. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3954-72.
34. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 1997;337:1584-90.
35. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000;105:71-7.
36. Radema SA, Beerepoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE. Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage [Abstract]. Proc Am Soc Clin Oncol 2002;21:439.
37. Heymach JV, Force JF, Beaudry P, et al. Effects of the VEGFR-2 tyrosine kinase inhibitor ZD6474 and docetaxel on circulating endothelial cells (CEC): Implications for use as a surrogate marker. Proc AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Abstract]. 2003;9:122.
38. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-ot-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999;5:2726-34.
39. Panigrahy D, Singer S, Shen LQ, et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 2002;110:923-32.
40. Motegi K, Harada K, Pazouki S, Baillie R, Schor AM. Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis. Histochem J 2002;34:411-21.
41. Benelli R, Morini M, Brigati C, Noonan DM, Albini A. Angiostatin inhibits extracellular HIV-Tat-rnduced inflammatory angiogenesis. Int J Oncol 2003;22:87-91.
42. Yamaguchi N, Anand AB, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999;18:4414-23.
43. Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, Ramanujam VM, Folkman J, Javaherian K. A 27-amino acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res 2005; 65:3656-63,
44. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771-80.
45. Bruns CJ, Koehl GE, Cuba M, et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004;10:2109-19.
46. Davis DW Shen Y, Mullani NA, et al. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004;10: 33-42.
47. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci U S A 2003; 100:4766-71.
48. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001;98:1024-9.
49. Kreuger J, Matsumoto T, Vanwildemeersch M, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J 2002;21:6303-11.